FDA's New Rules for Cheaper Copycat Drugs: Biosimilars Get a Guidance Boost
Published Date: 9/9/2025
Notice
Summary
The FDA just released final advice to help drug makers prove their new protein medicines are just as good as the originals. This update affects companies developing biosimilars by clarifying how to compare products and what info to include in their applications. It aims to speed up approval and save money by making the process clearer and more reliable.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Clarifies how to show biosimilarity
The FDA released final guidance explaining how drug makers should design and evaluate comparative analytical studies to show a therapeutic protein is biosimilar to a reference product licensed under the Public Health Service Act. The guidance finalizes and replaces the draft guidance issued May 22, 2019 and the prior final guidance issued April 30, 2015.
Specifies CMC info for biosimilar applications
The final guidance provides recommendations to sponsors on the scientific and technical information to include in the chemistry, manufacturing, and controls (CMC) section of a marketing application submitted under the Public Health Service Act. Sponsors developing therapeutic protein biosimilars should follow these CMC recommendations when preparing their applications.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in